EMAIL: SFeldman@olshanlaw.com
DIRECT DIAL: 212.451.2234
| June 10, 2021 |
VIA EMAIL AND EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Abby Adams and Tim Buchmiller |
| Division of Corporation Finance, | |
| Office of Life Sciences |
| Re: | Alzamend Neuro, Inc. Registration Statement on Form S-1 (No. 333-255955) Registration Statement on Form 8-A (No. 001- ) |
Ladies and Gentlemen:
On behalf of Alzamend Neuro, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statements to 4:00 p.m., Eastern time, on Monday, June 14, 2021, or as soon as possible thereafter.
Please advise the undersigned of the effectiveness of the Registration Statements.
| Very truly yours, | |
|
/s/ Spencer G. Feldman | |
| Spencer G. Feldman |
| cc: | Mr. Stephan Jackman Henry C.W. Nisser, Esq. |
ALZAMEND
NEURO, INC.
3802 Spectrum Boulevard, Suite 112C
Tampa, Florida 33612
| June 10, 2021 |
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Abby Adams and Tim Buchmiller |
| Division of Corporation Finance, | |
| Office of Life Sciences |
| Re: | Alzamend Neuro, Inc. Registration Statement on Form S-1 (No. 333-255955) Registration Statement on Form 8-A (No. 001- ) |
Ladies and Gentlemen:
Alzamend Neuro, Inc. hereby requests that the effectiveness of the above-referenced Registration Statements be accelerated so that they will become effective at 4:00 p.m., Eastern time, on Monday, June 14, 2021, or as soon as possible thereafter.
| Very truly yours, | ||
| ALZAMEND NEURO, INC. | ||
| By: |
/s/ Stephan Jackman | |
| Stephan Jackman | ||
| Chief Executive Officer | ||